In vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli
Autor: | Dennis G. Delgado, Carmen J. Brau, William E. Dismukes, C G Cobbs |
---|---|
Rok vydání: | 1979 |
Předmět: |
Cefotaxime
medicine.drug_class Cephalosporin Cefazolin Microbial Sensitivity Tests Penicillins Microbiology polycyclic compounds medicine Pharmacology (medical) Cefoxitin Cefamandole Pharmacology Mezlocillin Gram-Negative Aerobic Bacteria biology Chemistry Azlocillin biochemical phenomena metabolism and nutrition biology.organism_classification Proteus mirabilis Anti-Bacterial Agents Cephalosporins Aminoglycosides Infectious Diseases Research Article medicine.drug |
Zdroj: | Antimicrobial Agents and Chemotherapy. 16:864-868 |
ISSN: | 1098-6596 0066-4804 |
DOI: | 10.1128/aac.16.6.864 |
Popis: | A total of 434 clinical aerobic gram-negative bacillary isolates were tested against LY127935, a new 1-oxa cephalosporin, and compared with other cephalosporins, penicillins, and aminoglycosides by a broth microdilution technique. Cefotaxime (HR756), a new semisynthetic cephalosporin, and LY127935 were more active, and showed lower minimum inhibitory concentrations (ranges, less than or equal to 0.12 to 2.0 micrograms/ml), than cefamandole, cefoxitin, and cefazolin against Escherichia coli, Klebsiella spp., Enterobacter spp., Proteus mirabilis, indole-positive Proteus spp., Serratia marcescens, Providencia spp., and Citrobacter spp. Against P. aeruginosa, pepercillin, azlocillin, and mezlocillin were the most active beta-lactam agents; 64 micrograms/ml inhibited 99, 93, and 87% of the isolates, respectively. LY127935 and cefotaxime at 16 micrograms/ml inhibited 71% of Pseudomonas isolates, whereas the aminoglycosides gentamicin, tobramycin, and amikacin at a concentration of 4 micrograms/ml inhibited 84, 88, and 93%, respectively. Minimum bactericidal concentrations were determined for all isolates and were generally the same as the minimum inhibitory concentrations. |
Databáze: | OpenAIRE |
Externí odkaz: |